subject: Brazil Pharmaceutical Market Overview – Expanding healthcare access drives double-digit sales growth [print this page] Brazil's retailpharmaceutical market was valued at $12.6 billion in 2009, having grown by 14.3% between 2008 and 2009. Key growth drivers include the expanding population, improved access to healthcare, and the burgeoning middle class which is increasingly opting for branded drugs. Consequently, Big Pharma is targeting Brazil to off-set slowing sales growth in more developed markets.
Scope
Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing, reimbursement and intellectual property position in Brazil
Assesses the size of Brazil's pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies
Examines Brazil's generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion
Quantifies Brazil's R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis
Highlights
Brazil spent 10.8% of its GDP on both retail and hospital prescribed pharmaceuticals in 2009, reflecting the government's changing priorities, prioritizing healthcare including initiatives to expand access to medicines.
Intellectual property protection remains problematic for branded pharma, with issues associated with patent linkage, drawn out patent reviews, conflict between the two agencies involved in assessing patent applications, and the fact that there is no set period of data exclusivity.
Strong market growth in conjunction with improving regulatory standards has led to Brazil becoming a hotbed for investment from both multinational and domestic companies. Big Pharma players are gaining a stronger presence through M&A, expanding operations, and new product launches.
Reasons to Purchase
Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in Brazil.
Quantify the size and growth of the prescription pharmaceutical market in Brazil, analyzing key therapy areas, brands and companies.
Assess drivers and resistors of generic and biosimilars uptake in Brazil.
